PainReform Ltd. Ordinary Shares - PRFX STOCK NEWS

Welcome to our dedicated page for PainReform Ltd. Ordinary Shares news (Ticker: PRFX), a resource for investors and traders seeking the latest updates and insights on PainReform Ltd. Ordinary Shares stock.

PainReform Ltd. (symbol: PRFX) is a clinical-stage specialty pharmaceutical company dedicated to the development of innovative pain management solutions. The company focuses on the reformulation of established pain therapeutics, leveraging the US FDA 505(b)(2) regulatory pathway to bring enhanced products to market more efficiently.

The company’s flagship product, PRF-110, is designed to address the significant need for localized and extended post-operative pain relief. PRF-110 is a unique, oil-based, viscous solution containing the local anesthetic ropivacaine. This solution is applied directly into the surgical wound bed before closure, providing sustained pain relief and reducing the need for additional analgesics post-surgery.

PainReform applies proprietary technologies to improve the efficacy, reduce the adverse effects, and increase the convenience of pain medications. Their mission is to deliver pain therapeutics that offer clinically meaningful benefits to both physicians and patients.

Recent Achievements: PRF-110 has demonstrated superior formulation properties, particularly in terms of surface-tissue spreading, which is crucial for effective localized pain management. The company remains on track to announce top-line data from their clinical trials by mid-2024, indicating significant progress in their development timeline.

PainReform Ltd. continues to build strategic partnerships and collaborations to advance its product pipeline and bring new pain management solutions to market. By focusing on the reformulation of established drugs, the company aims to enhance patient outcomes and contribute positively to the field of pain management.